Breast cancer bone metastases: combination therapy targeting cancer cells and the tumor microenvironment.
Laboratory of Experimental Immunology, Cancer and Inflammation Program, National Cancer Institute-Frederick, Frederick, MD, USA
Rachel L
RL
de Kluyver
Thomas J
TJ
Sayers
D000818:Animals; D001859:Bone Neoplasms / Q000235:genetics / Q000556:secondary / Q000628:therapy*; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D004359:Drug Therapy, Combination; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D053245:RANK Ligand / Q000037:antagonists & inhibitors; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000235:genetics*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000235:genetics*; D059016:Tumor Microenvironment
D053245:RANK Ligand; C517736:Rank-Fc; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D053221:TNF-Related Apoptosis-Inducing Ligand